Everolimus rapalog study for healthy adults
Treatments studied
This early-phase study tests how a medicine called rapalog affects the body in generally healthy middle-aged adults. It may help researchers understand safety and dosing, but it’s not meant to treat an existing disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be a middle-aged adult and otherwise not have known chronic illnesses
- Be able to give informed consent and follow all study visits and rules
- Have a phone you can be reached on and be able to take pills by mouth
- Be able to keep your diet and usual activity level the same during the study
- Have blood test results showing good blood, liver, and kidney function
- If you are male: agree to prevent pregnancy during the study and for 4 weeks after
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a medication called sirolimus to see if it can help older adults stay healthy and independent. The trial is looking for people aged 65 and older who live at home and do not have serious memory problems or major health conditions like kidney or liver disease.
This trial tests two FDA-approved drugs, rapamycin and everolimus, to see if they can improve immune function in healthy older adults. You may join if you are generally healthy, live independently, and are between 65 and 90 years old.
This Phase 2 trial studies whether sirolimus can slow or prevent functional decline (more difficulty with daily activities) in older adults. You may be considered if you’re in the right age range and have no major heart, lung, liver, kidney, or recent bleeding/clotting problems.
This study tests a drug called everolimus to see if it helps treat vascular malformations (abnormal clusters of blood vessels). It is for adults aged 18 to 65 who have been diagnosed by MRI and are able to take oral medication.
This trial tests if everolimus can improve social abilities in people with PTEN germline mutations who have social difficulties. It may help those with PTEN Hamartoma Tumor Syndrome by targeting a specific pathway in the body.
This trial tests whether combining resistance training with the drug rapamycin can improve bone formation in postmenopausal women who have lower-than-normal bone density but not osteoporosis. It aims to find a new way to strengthen bones and prevent fractures.
Hear when a new Aging trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.